Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mozart Therapeutics

Request full access

Focuses on developing novel immune engagers

Seattle, United StatesFounded 2020Biotech & Life Sciences

About Mozart Therapeutics

Mozart Therapeutics, a privately held biopharmaceutical firm, was established in Seattle in June 2020 to engineer therapies for autoimmune and inflammatory conditions. The company's scientific foundation rests on the discoveries of its scientific co-founders from Stanford University: Mark M. Davis, Ph.D., K. Christopher Garcia, Ph.D., and Calvin Kuo, M.D., Ph.D. Their research identified a crucial network of immune cells, known as regulatory CD8 T cells (CD8 Tregs), that are essential for maintaining immune balance by identifying and eliminating cells that cause autoimmune disease. The company is led by President and CEO Katie Fanning, a biotech industry veteran with over 35 years of experience, including roles as CEO at Nohla Therapeutics and COO at VentiRx.

The company's business model is centered on the discovery, development, and eventual commercialization of these specialized therapeutics. Mozart has secured substantial funding to advance its pipeline, raising a total of $80 million through a Series A financing. The initial round of $55 million in October 2021 was led by ARCH Venture Partners and Sofinnova Partners, with participation from major pharmaceutical venture arms like Eli Lilly & Company, MRL Ventures Fund (Merck), and Leaps by Bayer. An additional $25 million was raised in June 2023 from new investors, including Pfizer Ventures and AbbVie Ventures.

Mozart's core product is a portfolio of CD8 Treg Modulators, which are engineered proteins designed to restore the normal function of the body's regulatory CD8 T cell network. Unlike broad immunosuppressants, these modulators are designed to selectively target the root cause of the autoimmune response without compromising the entire immune system. Their lead candidate, MTX-101, is a bispecific autoimmune checkpoint inhibitor that targets KIR and CD8 to restore the function of CD8 Tregs. This therapeutic is initially being developed for autoimmune gastrointestinal diseases, such as celiac disease, Crohn's disease, and ulcerative colitis. The company anticipated filing an Investigational New Drug (IND) application for MTX-101 and initiating Phase 1 human clinical trials in early 2024.

Source: Dealroom company data

At a glance

Status
Operational
Employees
37
Open positions
None listed
Dealroom signal
32.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
SaaS
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2023 $25M $275M AbbVie · UPMC Enterprises · Pfizer Ventures ↗
SERIES AOther financing Oct 2021 $55M $220M Sofinnova Partners · Altitude Life Science Ventures · Alexandria Venture Investments · MRL Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Mozart Therapeutics website traffic

Latest recorded traffic for Mozart Therapeutics is 2K monthly website visits, down 16.7% over the last three months. Mozart Therapeutics's team grew 0% over the past year.

Latest monthly visits2K 3-month web change-16.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Mozart Therapeutics in the Seattle ecosystem

Live from Dealroom

The Mozart Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States96.9%
🇦🇺 Australia3.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mozart Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mozart Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.